Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 3/20 | 0.47 |
| ▸ | EGFR | P00533 | 8/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | CD38 | P28907 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7118472 | 0.82 | EGFR (0.55) | RIPK2EGFRABCG2HTTTSHR | |
| SCHEMBL7127529 | 0.80 | RIPK2 (0.46) | RIPK2EGFRHTTLMNAKDM4E | |
| SCHEMBL7129801 | 0.80 | RIPK2 (0.48) | RIPK2EGFRHTTLMNAKDM4E | |
| SCHEMBL11091858 | 0.76 | EGFR (0.54) | EGFRABCG2HTTTSHRLMNA | |
| Hydrochloric Acid SCHEMBL11093405 | 0.75 | HTT (0.53) | EGFRABCG2HTTTSHRLMNA | |
| SCHEMBL7128053 | 0.74 | EGFR (0.42) | EGFRABCG2HTTTSHRLMNA | |
| SCHEMBL7124246 | 0.74 | RIPK2 (0.43) | RIPK2EGFRABCG2LMNAKDM4E | |
| SCHEMBL7125034 | 0.73 | RIPK2 (0.42) | RIPK2ABCG2TSHRLMNAKDM4E | |
| SCHEMBL7127650 | 0.72 | MAPT (0.46) | RIPK2HTTKDM4ETP53MAPT | |
| SCHEMBL7120296 | 0.71 | RIPK2 (0.41) | RIPK2EGFRABCG2MAPTNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 | RIPK2 3457/4885EGFR 319/4885ABCG2 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.